BMS steps into the European Market with its new Lung Cancer Treatment

21/07/2015 - 2 minutes

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC.

Just one month ago, BMS was granted with the first ever EU approval for its PD-1 inhibitor for the treatment of advanced melanoma. The same drug has now been authorized on the European market to treat patients suffering from metastatic NSCLC after prior chemotherapy.

Nivolumab not only reduces the risk of cancer by 41% versus the standard treatment alternative, docetaxel, but also enabled twice as many individuals to have survived the first year in comparison to chemotherapy (42% vs. 24%). Treatment-related adverse events also occur less frequently with nivolumab (58%) than its alternative docetaxel (86%). According to BMS, the inhibitor has therefore the potential to replace the current standard of care.

In Europe, incidence and mortality rates linked to lung cancer are on the rise,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member